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ON November 11, 1990, Stormie Jones died after a brief bout of what initially was thought to be a "flu 
syndrome." Later, it was realized that she had rejected her 
heart graft for reasons which are too complicated to 
summarize here. A memorial service was held on Novem-
ber 29, 1990, at the Children's Hospital of Pittsburgh for 
Stormie and other medical and surgical patients. For each 
child, a candle of remembrance was lit. My remarks were 
as follows: 
What Stormie Jones wanted was to be seen and treated like any 
other child. She might not approve of my saying something extra 
about her today, without doing the same thing for the others who 
are remembered here, also with a heavy heart. The special 
situation is that Stormie came to know everyone, or at least 
everyone knew her all over the world. She was the beautiful St. 
Valentine's Day card of February 14, 1984, the six-year-old 
God-sent child (and there is no other kind) with a name that movie 
starlets must have envied, a smile which no one who saw it could 
ever forget, and a courage great enough for five armies. She 
became a symbol for all those who suffered from heart disease, no 
matter what their age. At the age of 6, she had become the 
prisoner of Intensive Care U nits because of a kind of heart disease 
that usually is reserved for old people. She had reached this state 
because she was born with an inherited cholesterol defect that is 
reserved for the very young. When she was rescued in 1984 with 
a heart-liver transplantation, and again last year with a second 
liver, it brought hope to people of all ages. Along the way, her 
case established new principles about the intermediary metabo-
lism of cholesterol which were universally applicable. Thus, 
Stormie's life became a glorious one, and triumphant. 
We cannot confer immortality with our feeble efforts to help 
people. But Stormie did this by herself. The life she had was a full 
and happy one, filled with more meaning in 13 excitement-filled 
years than most people could cram into a hundred slow motion 
years. None of the children who are being remembered today will 
be forgotten by those who loved them. Perhaps at the head of that 
band heading toward the stars, can be seen the tow headed happy 
little 13-year-old girl who will be in the history books long after the 
rest of us are gone. We wanted more for her, but this was not to 
be. 
The lot of physicians who care for the desperately ill is 
to reconcile grief with the determination to make things 
better. Without the sense of personal loss that goes with a 
dear name and face, there is little progress and no incen-
tive for striving except personal or professional ambition. 
The field of transplantation is a young one and almost all 
those who contributed to this new clinical specialty are still 
alive. At our meetings, they remember what they did or 
failed to do by their patients' names, not with numbers or 
statistics. This is the power of the connection between the 
doctor and his patient. 
It also is the frailty. The cumulative weight of grief can 
be heavy no matter how few the losses or how frequent the 
successes which at first were few. At our conferences, the 
Greek legend is often cited of Icarus who tried to fly in 
defiance of mortal limitations, but fell when he came so 
close to the sun that his wax wings melted. This allusion 
still comes readily to the transplant surgeons who routinely 
provide treatment that had been considered beyond mortal 
achievement less than 30 years ago. The burn-out rate was 
high in the early days of transplantation. 
Because of this, and because aging spares no one, only 
a handful of workers in transplantation (myself included) 
have stayed in the field continuously throughout its 30-year 
modern history. We will never forget patients like Stormie 
Jones or the child, Julie Rodriguez, who in 1967 was the 
first long survivor after liver transplantation. But it would 
betray our memory of such patients to use their loss to 
excuse abandonment of efforts to move ahead. Conse-
quently, my own efforts during the rest of my professional 
life will continue to be in transplantation. 
At the University of Pittsburgh in 1986, a decision was 
made to strengthen and deepen the institutional commit-
ment to transplantation and programs which relate to it. 
An interdisciplinary Transplantation Council was formed 
to facilitate interaction between basic and clinical sci-
ences. Perpetuation of the already large kidney, liver, and 
heart programs and maintenance of quality control were 
the primary objectives, but not the only ones. The Council 
considered and fostered research of all kinds, including 
organ preservation, histocompatibility typing and match-
ing and, above all, the development of leads for better and 
safer control of rejection. One product of these efforts was 
FK 506, a new drug which is envisioned as a means of 
improving existing services and of achieving a number of 
previously unattainable objectives, such as intestinal 
transplantation. The development of FK 506 was made 
possible by a network of collaborating basic science and 
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clinical investigators within and outside the University. 
These same workers are now screening other new agents 
and techniques, with sophisticated end points of evalua-
tion that can ensure patient safety when and if the time 
comes for clinical application. 
We realized early on that transplantation research had 
pervasive applications which go far beyond organ grafting. 
The linkage which we described more than 20 years ago 
between the immunosuppression required for transplanta-
tion and the development of new malignancies became the 
focus of a secondary area of investigation, closely tied to 
the Pittsburgh Cancer Institute. A study of liver growth 
control factors, which resulted from efforts to define the 
optimal blood supply ofliver grafts also took on a life of its 
own. These growth factors, which are relevant to cancer 
research, may also be of importance in promoting the 
healing of damaged livers, thereby averting the need for 
transplantation. 
Our ultimate goal has been defined with greater clarity 
during the past 3 decades: the use of transplant-related 
advances to reduce the need for transplantation may, in 
the long run, supersede the results of direct transplant 
applications in numbers and in importance. A significant 
fraction of patients who need transplantation of the kid-
ney, liver, or heart have had their organs destroyed by 
so-called autoimmune diseases. In many of these condi-
tions, the disease causing organ destruction has been 
produced by a distortion or overactivity of the very same 
immunologic processes which cause graft rejection. Such 
processes have been controlled or stopped by immunosup-
pressive agents such as FK 506 and others. The list of 
these autoimmune diseases is a long one. Aside from those 
which lead to the destruction of commonly transplanted 
organs, a number of other medical disorders, such as 
psoriasis (a skin disorder), regional enteritis (affecting the 
bowel), rheumatoid arthritis, and multiple sclerosis are 
also potential candidates for treatment trials with agents 
such as FK 506. Juvenile diabetes mellitus is another 
disease which may be controlled, provided that therapy is 
started during the so-called "honeymoon period," within 
the first few days after the diagnosis is made. This kind of 
intervention with FK 506 for patients with recent onset 
diabetes has been authorized by the US Food and Drug 
Administration, and was begun in Pittsburgh in November 
1990. 
Returning to transplantation, the next great surge, al-
ready underway with bone marrow, will be with cells (as 
opposed to whole organ engraftment). Many diseases, and 
especially those caused by inborn errors of metabolism, 
may be cured by the less dangerous transfer of cells, 
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should these techniques be perfected as we antiCIpate, 
within the next decade. One immediate example almost 
one year ago at Pittsburgh, was the first successful in-
stance of pancreatic islet cell transplantation. This previ-
ously elusive goal has now been attained at 3 other medical 
centers. With the use of liver cells instead of a whole liver, 
Stormie Jones' original disease of hypercholesterolemia 
might have been treatable-as just one of these examples. 
Even cell transplantation, however, cannot be viewed in 
isolation. Using gene transfer techniques, cells (including 
cells removed, treated, and returned to the same patient) 
can be modified in desired ways in order to endow them 
with the specific functions and characteristics which they 
are missing, thereby treating a variety of well-defined 
genetically determined diseases, including inborn errors of 
metabolism and cancer. This revolutionary approach to 
gene therapy is a logical outgrowth of the transplantation 
effort. 
The institutional decisions made in Pittsburgh in 1986 
subsequently led to my appointment as President of the 
Transplantation Council, and changed my own profes-
sional life. While still a surgeon, my activities have now 
become focused increasingly on research and development 
in these many interrelated areas. Between 1986 and today, 
I first recruited and trained a number of surgical teams with 
unparalleled technical and management skills who can 
continue to provide clinical services of the highest order in 
all components of organ transplantation. We have now 
institutionalized a surgical program which, at one time, 
was isolated and highly dependent on very few people. 
Today, I participate surgically only in cases with unusual 
problems, or in operations which are not as yet completely 
worked out. With all of these elements in place, the 
University of Pittsburgh now has formed a Transplanta-
tion Institute, which has become my professional home. 
The cornerstone of the Institute's purpose is to continue 
the evolutionary process of experimental and clinical or-
gan and cellular transplantation, with all of their ramifica-
tions. 
There will be a unique opportunity in the decades ahead 
to justify the major public support, including grant funding 
for research, without which none of the progress in trans-
plantation of the last 30 years would have been possible. 
The dividends of the transplantation effort, in terms of its 
influence on the overall practice of medicine, have greatly 
exceeded even my own youthful fantasies. It is my hope to 
continue to participate in the momentum which has now 
gathered, as we stand on the threshold of the new era in 
medical therapy which has been heralded by recent ad-
vances in organ and cellular transplantation. 
